1University College London, London, UK.
J Psychopharmacol. 2014 Mar;28(3):270-81. doi: 10.1177/0269881113495722. Epub 2013 Jul 11.
Genetically-altered mice, lacking functional NK1 receptors (NK1R-/-), express abnormal behaviours that are prominent in Attention Deficit Hyperactivity Disorder: namely, inattentiveness and impulsivity (indicated by their greater % omissions and premature responses in the 5-Choice Serial Reaction-Time Task (5-CSRTT) and locomotor hyperactivity. We investigated how behaviour in the 5-CSRTT is affected by repeated testing and whether the abnormalities expressed by NK1R-/- mice are mimicked by treating wild type mice with a NK1R antagonist (L 733060 or RP 67580; 5 or 10 mg/kg). Repeated testing with a variable (VITI) or fixed, prolonged (LITI) intertrial interval reduced % omissions. Premature responses also declined, but only in NK1R-/- mice, in the VITI test. By contrast, perseveration increased in both genotypes. RP 67580 (10 mg/kg) increased the % omissions in both genotypes in the VITI, an action which cannot be attributed to NK1R antagonism. Neither drug affected perseveration. However, for premature responses, the response profile suggested that the low and high doses of RP 67580 (VITI) and L 733060 (LITI) had opposing effects on this behaviour. We infer that the effect of NK1R antagonists in the 5-CSRTT is confounded by animals' test experience and non-specific drug effects at sites other than NK1R, possibly L-type Ca²⁺(v) channels.
基因改造缺乏功能性 NK1 受体(NK1R-/-)的小鼠表现出异常行为,这些行为在注意力缺陷多动障碍中尤为突出:即注意力不集中和冲动(表现在他们在 5-选择连续反应时间任务(5-CSRTT)中的更大的遗漏百分比和过早反应,以及运动过度。我们研究了重复测试如何影响 5-CSRTT 中的行为,以及 NK1R-/- 小鼠表达的异常是否被用 NK1R 拮抗剂(L 733060 或 RP 67580;5 或 10 mg/kg)治疗的野生型小鼠所模拟。用可变(VITI)或固定、延长(LITI)的试验间间隔重复测试减少了遗漏百分比。过早反应也下降,但仅在 VITI 测试中,NK1R-/- 小鼠的反应下降。相比之下,两种基因型的坚持反应都增加了。RP 67580(10 mg/kg)在 VITI 中增加了两种基因型的遗漏百分比,这种作用不能归因于 NK1R 拮抗作用。两种药物都没有影响坚持反应。然而,对于过早反应,反应模式表明,RP 67580 的低剂量和高剂量(VITI)和 L 733060(LITI)对这种行为有相反的影响。我们推断,NK1R 拮抗剂在 5-CSRTT 中的作用受到动物测试经验和非 NK1R 部位的非特异性药物作用的混淆,可能是 L 型钙通道(v)。